Canada
· Delayed Price · Currency is CAD Medicenna Therapeutics Statistics
Total Valuation
Medicenna Therapeutics has a market cap or net worth of CAD 145.75 million. The enterprise value is 128.77 million.
| Market Cap | 145.75M |
| Enterprise Value | 128.77M |
Important Dates
The next estimated earnings date is Friday, August 2, 2024.
| Earnings Date | Aug 2, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Medicenna Therapeutics has 76.71 million shares outstanding. The number of shares has increased by 7.57% in one year.
| Shares Outstanding | 76.71M |
| Shares Change (YoY) | +7.57% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 15.40% |
| Owned by Institutions (%) | 0.44% |
| Float | 49.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 25.49 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.06 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.37
| Current Ratio | 1.37 |
| Quick Ratio | 1.30 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -146.88% and return on invested capital (ROIC) is -67.31%.
| Return on Equity (ROE) | -146.88% |
| Return on Assets (ROA) | -42.00% |
| Return on Capital (ROIC) | -67.31% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.59M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3.31M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +216.67% in the last 52 weeks. The beta is 1.31, so Medicenna Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.31 |
| 52-Week Price Change | +216.67% |
| 50-Day Moving Average | 2.19 |
| 200-Day Moving Average | 1.23 |
| Relative Strength Index (RSI) | 44.94 |
| Average Volume (20 Days) | 85,320 |
Short Selling Information
The latest short interest is 222,810, so 0.29% of the outstanding shares have been sold short.
| Short Interest | 222,810 |
| Short Previous Month | 150,128 |
| Short % of Shares Out | 0.29% |
| Short % of Float | 0.45% |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -18.67M |
| Pretax Income | -25.47M |
| Net Income | -25.47M |
| EBITDA | -18.67M |
| EBIT | -18.67M |
| Earnings Per Share (EPS) | -0.37 |
Balance Sheet
| Cash & Cash Equivalents | 16.98M |
| Total Debt | n/a |
| Net Cash | 16.98M |
| Net Cash Per Share | 0.22 |
| Equity (Book Value) | 5.19M |
| Book Value Per Share | 0.07 |
| Working Capital | 5.13M |
Cash Flow
| Operating Cash Flow | -16.26M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Medicenna Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.57% |
| Shareholder Yield | -7.57% |
| Earnings Yield | -19.25% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on March 3, 2017. It was a reverse split with a ratio of 0.0714285.
| Last Split Date | Mar 3, 2017 |
| Split Type | Reverse |
| Split Ratio | 0.0714285 |